stockrowNovo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) Return on invested capital
Novo Nordisk A/S's return on invested capital over the twelve months to 30 June 2026 was 28.7%, up 1.3 percentage points from fiscal 2025 (27.4%). Over the past ten years it has ranged from 27.4% (fiscal 2025) to 124.7% (fiscal 2016) — the current reading is the lowest in ten years. That is above the Drug Manufacturers General industry median of 6.26% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 27.4% | (10.17) |
| FY2024 | 37.6% | (25.93) |
| FY2023 | 63.5% | 7.13 |
| FY2022 | 56.4% | 9.49 |
| FY2021 | 46.9% | (8.67) |
| FY2020 | 55.5% | (15.14) |
| FY2019 | 70.7% | (10.21) |
| FY2018 | 80.9% | (19.95) |
| FY2017 | 100.8% | (23.89) |
| FY2016 | 124.7% | 11.41 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVO Novo Nordisk A/S | 28.7% |
| AMGN Amgen Inc. compare | 14.3% |
| BMY Bristol Myers Squibb Company compare | 13.2% |
| AZN AstraZeneca PLC compare | 12.3% |
| NVS Novartis AG compare | 12.1% |
| GSK GSK PLC Sponsored ADR compare | 9.61% |
| SNY Sanofi compare | 7.05% |
| PFE Pfizer Inc. compare | 6.19% |
| GILD Gilead Sciences, Inc. compare | −4.51% |
| Drug Manufacturers General industry median | 6.26% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on NVO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement